ProCE Banner Activity

Podcast Pearls: Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

Slideset Download
Download this slideset to learn more about the clinical trials discussed in our podcast focused on PARP inhibitor combination approaches to broaden the utility of PARP inhibition in prostate cancer.

Released: April 19, 2021

Expiration: April 18, 2022

No longer available for credit.

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Joaquin Mateo

Joaquin Mateo, MD, PhD

Group Leader
Prostate Cancer Translational Research
Vall d Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d Hebron University Hospital
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentech, Janssen, MSD, Orion, and Sanofi.

Joaquin Mateo, MD, PhD

Group Leader
Prostate Cancer Translational Research
Vall d Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d Hebron University Hospital
Barcelona, Spain

Joaquin Mateo, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Clovis, Guardant Health, Janssen, MSD, Pfizer, and Roche; funds for research support from AstraZeneca; and fees for non-CME/CE services from AstraZeneca, Guardant Health, Janssen, MSD, and Pfizer.